BRIEF published on 12/11/2025 at 23:05, 5 months 8 days ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 5 months 8 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 5 months 8 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 6 months 1 day ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 6 months 1 day ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 6 months 1 day ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 6 months 7 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 6 months 7 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 6 months 7 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 7 months 10 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 05/20/2026 at 15:28, 3 hours 10 minutes ago Sarama Resources Announces Private Equity Placement of A$1.5m
Published on 05/20/2026 at 15:01, 3 hours 37 minutes ago Kidoz Inc. Appoints Tarrnie Williams Jr. as Chief Operating Officer
Published on 05/20/2026 at 15:00, 3 hours 38 minutes ago BlackBerry Achieves FedRAMP Class D (High) Re-Certification as Government Demand for Mission-Critical Communications Grows
Published on 05/20/2026 at 14:00, 4 hours 38 minutes ago Ameriwest to Advance Its Bornite Copper Project by Re-Logging and Re-Assaying Historical Drill
Published on 05/20/2026 at 14:00, 4 hours 38 minutes ago First Canadian Graphite Reports Encouraging Results at Lac Guéret South from Airborne Survey Indicating Significant Expansion Possibilities
Published on 05/20/2026 at 17:48, 50 minutes ago Commerzbank Annual General Meeting approves all agenda items
Published on 05/20/2026 at 17:46, 51 minutes ago Commerzbank Annual General Meeting approves all agenda items
Published on 05/20/2026 at 17:45, 53 minutes ago REALITES: Prorogation du délai de complétude des informations nécessaires à la conversion de créances en actions nouvelles
Published on 05/20/2026 at 17:40, 58 minutes ago Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.26.
Published on 05/20/2026 at 17:13, 1 hour 25 minutes ago Original-Research: Reply SpA (von Quirin Privatbank Kapitalmarktgeschäft): Buy
